13 / 22
Orthopedics and Osteoporosis 2018
N o v e m b e r 2 9 - 3 0 , 2 0 1 8
Am s t e r d a m , N e t h e r l a n d s
Page 63
Journal of Clinical & Experimental Orthopaedics
ISSN: 2471-8416
E u r o p e a n C o n f e r e n c e o n
Orthopedics and
Osteoporosis
T
he interleukin 12
(IL-12)
family is unique in having the only heterodimeric cytokines, including
IL-12
,
IL-23
,
IL-27
and
IL-35
.
Despite sharing many structural features and molecular partners,
IL-12
family cytokines have diverse functional effects.
Both
IL-12
and
IL-23
are pro-inflammatory, and have been implicated in a number of autoimmune diseases. Monoclonal antibody
against
IL-12/IL23
(Ustekinumab) has been used for treatment of psoriatic arthritis.
IL-23
deficient mice were found to be protected
against development of collagen induced arthritis and moreover
IL-17
producing CD4
+
T cells were absent in
IL-23
deficient mice.
The remaining two cytokines of the family,
IL-27
and
IL-35
are pre-dominantly anti-inflammatory in nature. Studies have shown
that deletion of
IL-27
receptor in mice leads to excessive
Th17
responses in experimental autoimmune encephalomyelitis (EAE).
IL-27
also has been reported to provide protection against collagen-induced arthritis and rheumatoid arthritis by suppressing
Th17
cells and augmenting T regulatory cell differentiation. Apart from
IL-27
,
IL-35
, serum levels are found to be quite low in conditions
of rheumatoid arthritis patients. While all these cytokines have diverse functions, their role in post-menopausal osteoporosis was
not looked into. Our group has determined the role of
IL-27
cytokine and
IL-23
neutralizing antibody in estrogen deficiency induced
bone loss conditions. Our studies revealed the osteoprotective effects of
IL-27
and anti-
IL 23
antibody by suppression of
Th17
differentiation, the major osteoclastogenic T helper subset and restoration of ovariectomy induced deterioration of trabecular
bone microarchitecture. Our studies form a strong basis for using humanized
IL-27
or neutralizing
IL-23
antibody towards the
treatment of postmenopausal osteoporosis.
divya_singh@cdri.res.inIL-12
cytokine family: new players in pathogenesis
of osteoporosis
Divya Singh
Central Drug Research Institute, India
J Clin Exp Orthop 2018, Volume: 4
DOI: 10.4172/2471-8416-C1-006